MedTrace Logo

COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma

NCT04357106 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-04-22

No results posted yet for this study

Summary

COVID-19 disease has become a very serious global health problem. Treatments for severe forms are urgently needed to lower mortality. Any procedure that improves these forms should be considered, especially those devoid of serious side effects.There is not enough published information on the use of allogeneic convalescent plasma (ACP) in the treatment of severe forms of COVID-19. The use of ACP can be combined with other treatments and has very few adverse effects. It takes 10-14 days for SARS-CoV2-infected patients to produce virus-neutralizing antibodies: within that time they can develop serious complications and die. Injecting PAC into patients with severe forms of COVID-19 shortens the period of risk while the patient produces the antibodies.

Conditions

Interventions

BIOLOGICAL

Convalescent plasma

Convalescent plasma obtained by aphaeresis from recovered patients.

Sponsors & Collaborators

  • Laboratorios Clínicos de Puebla (Laboratorios Ruiz)

    collaborator UNKNOWN

  • Centro de Hematología y Medicina Interna

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-13
Primary Completion
2020-07-31
Completion
2020-08-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04357106 on ClinicalTrials.gov